迈威生物：与Kalexo签署独家许可协议 公司将获得最高10亿美元预付款和里程碑付款

Core Viewpoint - The company, Maiwei Biotech, has signed exclusive licensing and preferred stock purchase agreements with Kalexo Bio, Inc. for the 2MW7141 project, allowing Kalexo exclusive rights for global development, production, and commercialization of the licensed product [1] Group 1: Agreements and Financial Terms - The licensing agreement includes a potential total of up to $1 billion in upfront and milestone payments from Kalexo [1] - The initial payment consists of a non-refundable upfront payment and near-term payment of $12 million in cash [1] - Additionally, the company will receive double-digit preferred shares in Kalexo as part of the agreement, contingent upon meeting specified conditions [1]